Literature DB >> 15894660

A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors.

Karin Collett1, Ingunn M Stefansson, Johan Eide, Audun Braaten, Hege Wang, Geir Egil Eide, Steinar Ø Thoresen, William D Foulkes, Lars A Akslen.   

Abstract

Interval breast cancer reduce the effectiveness of mammography screening programs. We studied 95 interval cancers, diagnosed during 1996 to 2001 as part of the population-based Norwegian Breast Cancer Screening Program. These cases were matched on size (+/-2.0 mm) to 95 screen-detected breast cancers, and the tumors were compared by immunohistochemical methods using tissue microarrays. Patients with interval cancers were more likely to be younger [odds ratio (OR), 4.7; P = 0.0001], to have dense breasts (OR, 3.4; P = 0.004), and to have estrogen receptor-negative tumors (OR, 2.6, P = 0.01), and p53 expression was more frequent (OR, 4.0; P = 0.001). Notably, interval cancers were more likely to have a basal epithelial phenotype, in that expression of cytokeratin 5/6 (OR, 2.3; P = 0.04) and P-cadherin (OR, 2.5; P = 0.04) was more frequent in interval cases than in size-matched, screen-detected tumors. In a logistic regression model, p53 expression, age, and breast density were independent predictors of interval cancers. Our data suggest that breast cancers with a basal epithelial phenotype are more likely than nonbasal breast cancers to present between regular mammograms.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15894660     DOI: 10.1158/1055-9965.EPI-04-0394

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  65 in total

Review 1.  Triple-negative breast cancer: present challenges and new perspectives.

Authors:  Franca Podo; Lutgarde M C Buydens; Hadassa Degani; Riet Hilhorst; Edda Klipp; Ingrid S Gribbestad; Sabine Van Huffel; Hanneke W M van Laarhoven; Jan Luts; Daniel Monleon; Geert J Postma; Nicole Schneiderhan-Marra; Filippo Santoro; Hans Wouters; Hege G Russnes; Therese Sørlie; Elda Tagliabue; Anne-Lise Børresen-Dale
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

2.  How do I treat "triple-negative" disease.

Authors:  Christos Vaklavas; Andres Forero-Torres
Journal:  Curr Treat Options Oncol       Date:  2011-12

3.  Re. Multimodality breast cancer screening in women with a familial or genetic predisposition.

Authors:  S A Narod
Journal:  Curr Oncol       Date:  2010-11       Impact factor: 3.677

Review 4.  Molecular therapy of breast cancer: progress and future directions.

Authors:  Sheng-Xiang Lin; Jiong Chen; Mausumi Mazumdar; Donald Poirier; Cheng Wang; Arezki Azzi; Ming Zhou
Journal:  Nat Rev Endocrinol       Date:  2010-07-20       Impact factor: 43.330

5.  PAM50 and Risk of Recurrence Scores for Interval Breast Cancers.

Authors:  Samantha Puvanesarajah; Sarah J Nyante; Cherie M Kuzmiak; Mengjie Chen; Chiu-Kit Tse; Xuezheng Sun; Emma H Allott; Erin L Kirk; Lisa A Carey; Charles M Perou; Andrew F Olshan; Louise M Henderson; Melissa A Troester
Journal:  Cancer Prev Res (Phila)       Date:  2018-04-05

6.  Dermcidin expression is associated with disease progression and survival among breast cancer patients.

Authors:  Heather Ann Brauer; Monica D'Arcy; Tanya E Libby; Henry J Thompson; Yutaka Y Yasui; Nobuyuki Hamajima; Christopher I Li; Melissa A Troester; Paul D Lampe
Journal:  Breast Cancer Res Treat       Date:  2014-02-22       Impact factor: 4.872

7.  Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.

Authors:  Christopher I Li; Justin E Mirus; Yuzheng Zhang; Arturo B Ramirez; Jon J Ladd; Ross L Prentice; Martin W McIntosh; Samir M Hanash; Paul D Lampe
Journal:  Breast Cancer Res Treat       Date:  2012-08-19       Impact factor: 4.872

8.  Organized screening detects breast cancer at earlier stage regardless of molecular phenotype.

Authors:  Claire M B Holloway; Li Jiang; Marlo Whitehead; Jennifer M Racz; Patti A Groome
Journal:  J Cancer Res Clin Oncol       Date:  2018-06-16       Impact factor: 4.553

9.  QSOX1 expression is associated with aggressive tumor features and reduced survival in breast carcinomas.

Authors:  Gøril Knutsvik; Karin Collett; Jarle Arnes; Lars A Akslen; Ingunn M Stefansson
Journal:  Mod Pathol       Date:  2016-08-26       Impact factor: 7.842

10.  Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival.

Authors:  S J Dawson; S W Duffy; F M Blows; K E Driver; E Provenzano; J LeQuesne; D C Greenberg; P Pharoah; C Caldas; G C Wishart
Journal:  Br J Cancer       Date:  2009-09-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.